Kaleido Biosciences(KLDO)
$0.000.00 (0.00%)
KLDO
Kaleido Biosciences financials statements
$0.00
At close:0.00 (0.00%)
Kaleido Biosciences (KLDO) Ratios
196 Followers
Kaleido Biosciences Ratios
KLDO's free cash flow for Q4 2021 was $-17.60M. For the 2021 fiscal year, KLDO's free cash flow was decreased by $-436.00K and operating cash flow was $-17.16M. See a summary of the company’s cash flow.
| Ratios | Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.43 | 2.92 | 7.06 | 6.75 | 7.41 |
| Quick Ratio | 1.43 | 2.92 | 7.06 | 6.75 | 7.41 |
| Cash Ratio | 1.30 | 2.77 | 6.87 | 6.73 | 7.38 |
| Solvency Ratio | -2.22 | -2.05 | -2.50 | -2.25 | -0.37 |
| Operating Cash Flow Ratio | -2.60 | -3.69 | -7.30 | -4.10 | -5.84 |
| Short-Term Operating Cash Flow Coverage | -4.78 | -23.36 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 2.78M | $ 9.87M | $ 39.86M | $ 49.11M | $ -45.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.43 | 0.35 | 0.25 | 0.17 | 0.49 |
| Debt-to-Equity Ratio | 2.05 | 1.03 | 0.42 | 0.26 | -0.34 |
| Debt-to-Capital Ratio | 0.67 | 0.51 | 0.30 | 0.20 | -0.52 |
| Long-Term Debt-to-Capital Ratio | 0.34 | 0.47 | 0.29 | 0.20 | -0.51 |
| Financial Leverage Ratio | 4.73 | 2.90 | 1.68 | 1.47 | -0.70 |
| Debt Service Coverage Ratio | -4.48 | -14.16 | -86.01 | -58.68 | -61.16 |
| Interest Coverage Ratio | -30.89 | -28.15 | -88.70 | -60.38 | -62.14 |
| Debt to Market Cap | 0.22 | 0.07 | 0.16 | 0.04 | 0.05 |
| Interest Debt Per Share | 0.59 | 0.71 | 0.83 | 0.54 | 0.68 |
| Net Debt to EBITDA | 0.20 | 0.33 | 0.60 | 1.04 | 0.51 |
| Profitability Margins | |||||
| Gross Profit Margin | -113.59% | -5640.21% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -7921.20% | -8083.90% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -7707.61% | -7896.92% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -7940.85% | -8089.64% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -8178.26% | -8371.28% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -8178.26% | -8371.28% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -8178.26% | -8371.28% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 98.47% | 100.00% | 100.00% |
| EBT Per EBIT | 102.99% | 103.48% | 99.62% | 101.75% | 101.96% |
| Return on Assets (ROA) | -180.08% | -137.54% | -103.29% | -72.36% | -89.63% |
| Return on Equity (ROE) | -851.21% | -398.22% | -173.91% | -106.10% | 63.09% |
| Return on Capital Employed (ROCE) | -428.58% | -184.78% | -120.48% | -81.98% | -100.51% |
| Return on Invested Capital (ROIC) | -239.53% | -164.95% | -120.37% | -81.80% | -99.78% |
| Return on Tangible Assets | -172.05% | -132.10% | -103.29% | -72.36% | -89.63% |
| Earnings Yield | -90.25% | -26.81% | -65.89% | -14.76% | -8.64% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.42 | 0.01 | 0.65 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.19 | 0.12 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.05 | 0.02 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -877.67 | -35145.44 | -558.30 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 877.67 | 35145.44 | 558.30 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.84 | -1.84 | -2.95 | -1.58 | -1.00 |
| Free Cash Flow Per Share | -1.87 | -1.96 | -3.09 | -1.68 | -1.07 |
| Dividend Paid and CapEx Coverage Ratio | -68.29 | -15.29 | -21.14 | -15.43 | -16.00 |
| Capital Expenditure Coverage Ratio | -68.29 | -15.29 | -21.14 | -15.43 | -16.00 |
| Operating Cash Flow Coverage Ratio | -3.55 | -2.93 | -3.70 | -3.10 | -1.51 |
| Operating Cash Flow to Sales Ratio | -69.83 | -63.10 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -78.19% | -21.53% | -61.52% | -11.79% | -7.49% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.11 | -3.73 | -1.52 | -6.77 | -11.58 |
| Price-to-Sales (P/S) Ratio | 90.62 | 312.20 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 9.43 | 14.85 | 2.64 | 7.19 | -7.30 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -1.28 | -4.64 | -1.63 | -8.48 | -13.35 |
| Price-to-Operating Cash Flow Ratio | -1.30 | -4.95 | -1.70 | -9.03 | -14.18 |
| Price-to-Earnings Growth (PEG) Ratio | 0.10 | 0.14 | -0.03 | -0.10 | -0.06 |
| Enterprise Value Multiple | -0.98 | -3.63 | -0.93 | -6.05 | -11.44 |
| Enterprise Value | 83.27M | 279.18M | 78.25M | 357.12M | 305.46M |
| EV to EBITDA | -0.98 | -3.63 | -0.93 | -6.05 | -11.44 |
| EV to Sales | 75.42 | 286.34 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -1.06 | -4.26 | -0.99 | -7.24 | -12.78 |
| EV to Operating Cash Flow | -1.08 | -4.54 | -1.03 | -7.71 | -13.58 |
| Tangible Book Value Per Share | 0.25 | 0.61 | 1.90 | 1.98 | -1.95 |
| Shareholders’ Equity Per Share | 0.25 | 0.61 | 1.90 | 1.98 | -1.95 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -2.16 | -2.44 | -3.31 | -2.10 | -1.23 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 1.00 | 1.00 |
| Interest Burden | 1.03 | 1.04 | 1.01 | 1.02 | 1.02 |
| Research & Development to Revenue | 61.42 | 57.40 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 18.99 | 24.49 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 9.37 | 13.01 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.85 | 0.75 | 0.88 | 0.75 | 0.82 |
Currency in USD

